Everything you care about in one place
Follow feeds: blogs, news, RSS and more. An effortless way to read and digest content of your choice.
Get Feederir.akerotx.com
Akero Therapeutics News Releases
Get the latest updates from Akero Therapeutics News Releases directly as they happen.
Follow now 36 followers
Latest posts
Last updated 2 days ago
Akero Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update
2 days ago
Phase 2b SYMMETRY study preliminary results showed statistically significant reversal of compensated...
Akero Therapeutics and HistoIndex Present New Analyses of Phase 2b HARMONY Trial in Oral and Poster Presentations at the EASL Congress 2025
4 days ago
Analysis of EFX results with AI-based digital pathology underscores the potential value...
Akero Therapeutics Announces Publication of Phase 2b SYMMETRY Trial in the New England Journal of Medicine
5 days ago
Results support potential benefit of efruxifermin (EFX) to elicit fibrosis improvement in...
Akero Therapeutics Presents Week 96 Results from Phase 2b SYMMETRY Clinical Trial of Efruxifermin in Patients with Compensated Cirrhosis Caused by MASH Showing Fibrosis Improvement without Worsening of MASH at the EASL Congress 2025
5 days ago
SOUTH SAN FRANCISCO, Calif., May 09, 2025 (GLOBE NEWSWIRE) -- Akero Therapeutics...
Akero Therapeutics to Present at the BofA Securities 2025 Healthcare Conference
7 days ago
SOUTH SAN FRANCISCO, Calif., May 07, 2025 (GLOBE NEWSWIRE) -- Akero Therapeutics...
Akero Therapeutics Announces Upcoming Poster and Oral Presentations at the EASL Congress 2025
14 days ago
SOUTH SAN FRANCISCO, Calif., April 30, 2025 (GLOBE NEWSWIRE) -- Akero Therapeutics...
Akero Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
2 months ago
-- Reported unprecedented, statistically significant reversal of compensated cirrhosis (F4) due to...
Akero Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of Underwriters’ Option to Purchase Additional Shares
3 months ago
SOUTH SAN FRANCISCO, Calif., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Akero Therapeutics...
Akero Therapeutics Announces Pricing of Upsized Public Offering of Common Stock and Pre-Funded Warrants
4 months ago
SOUTH SAN FRANCISCO, Calif., Jan. 28, 2025 (GLOBE NEWSWIRE) -- Akero Therapeutics...
Akero Therapeutics Announces Proposed Public Offering of Common Stock
4 months ago
SOUTH SAN FRANCISCO, Calif., Jan. 27, 2025 (GLOBE NEWSWIRE) -- Akero Therapeutics...
Akero Therapeutics Reports Preliminary Topline Results Showing Statistically Significant Reversal of Compensated Cirrhosis (F4) Due to MASH—by Both Completer and ITT Analyses—at Week 96 in Phase 2b SYMMETRY Study
4 months ago
Among patients with baseline and week 96 biopsies, 39% of the 50mg...
Akero Therapeutics to Present Preliminary Topline Week 96 Results from Phase 2b SYMMETRY Study Investigating Efruxifermin in Patients with Compensated Cirrhosis (F4) Due to MASH
4 months ago
Investor webcast on Monday, January 27, 2025, at 8:00 a.m. ET to...